H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $20 from $32 and keeps a Buy rating on the shares following the Q1 report.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance downgraded to Market Perform from Outperform at Citizens JMP
- Iovance Biotherapeutics Reports Q1 2025 Financial Results
- Iovance Biotherapeutics: Buy Rating Amid Signs of Recovery and Growth Potential
- Closing Bell Movers: Pinterest jumps 15%, Toast up 7% after earnings
- Iovance Biotherapeutics reports Q1 EPS (36c), consensus (23c)